Lasers in skin cancer prophylaxis

References

• Bickers DR, Lim HW, Margolis D. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol.55(3), 490–500 (2006).
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J. Am. Acad. Dermatol.42(1 Pt 2), 23–24 (2000).
   PubMed Web of Science ®Google Scholar
• Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res.63(8), 1727–1730 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson JA, Scott D, Wharton J, Sell S. Incidental histopathologic patterns: possible evidence of ‘field cancerization’ surrounding skin tumors. Am. J. Dermatopathol.23(5), 494–496 (2001).
   PubMed Web of Science ®Google Scholar
• Kanjilal S, Strom SS, Clayman GL et al. p53 mutations in non-melanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res.55(16), 3604–3609 (1995).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol.50(5), 714–721 (2004).
   PubMed Web of Science ®Google Scholar
• Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol.50(5), 722–733 (2004).
   PubMed Web of Science ®Google Scholar
• Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod; an international update on therapeutic uses in dermatology. Int. J. Dermatol.41(11), 810–816 (2002).
   PubMed Web of Science ®Google Scholar
• Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl Cancer Inst.95(15), 1138–1149 (2003).
   PubMed Web of Science ®Google Scholar
• Ambach A, Bonnekoh B, Nguyen M, Schon MP, Gollnick H. Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.Mol. Immunol.40(18), 1307–1314 (2004).
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Tuzun Y, Wolf R. Retinoid receptors. Dermatol. Clin.25(4), 525–530, viii (2007).
   PubMed Web of Science ®Google Scholar
• De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol. Surg.30(4 Pt 2), 656–661 (2004).
   PubMed Web of Science ®Google Scholar
• Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin. Drug Saf.7(2), 167–172 (2008).
   PubMed Web of Science ®Google Scholar
• Ulrich C, Hackethal M, Ulrich M et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br. J. Dermatol.156(Suppl. 3) 40–42 (2007).
   PubMed Web of Science ®Google Scholar
• Nelson CG, Spencer J, Nelson CG Jr. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J. Drugs Dermatol.6(7), 712–717 (2007).
   PubMedGoogle Scholar
• Weinberg JM. Topical therapy for actinic keratoses: current and evolving therapies. Rev. Recent Clin. Trials1(1), 53–60 (2006).
   PubMedGoogle Scholar
• Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur. J. Dermatol.16(6), 599–606 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J. Drugs Dermatol.3(4), 401–407 (2004).
   PubMedGoogle Scholar
• Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for non-melanoma skin cancer prophylaxis. Arch. Dermatol.142(8), 976–982 (2006).
   PubMedGoogle Scholar
• Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol. Surg.23(3), 191–196 (1997).
   PubMed Web of Science ®Google Scholar
• Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol. Surg.23(10), 885–889 (1997).
   PubMed Web of Science ®Google Scholar
• Massey RA, Eliezri YD. A case report of laser resurfacing as a skin cancer prophylaxis. Dermatol. Surg.25(6), 513–516 (1999).
   PubMed Web of Science ®Google Scholar
• Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG. Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol. Surg.25(9), 729–732 (1999).
   PubMed Web of Science ®Google Scholar
• Field LM. The superiority of dermabrasion over laser abrasion in the prophylaxis of malignant and premalignant disease. Dermatol. Surg.33(2), 258–259 (2007).
   PubMed Web of Science ®Google Scholar
• Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg. Med.34(2), 114–119 (2004).
   PubMed Web of Science ®Google Scholar
• Ostertag JU, Quaedvlieg PJ, Neumann MH, Krekels GA. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol. Surg.32(2), 261–267 (2006).
   PubMed Web of Science ®Google Scholar
• Orenstein A, Goldan O, Weissman O, Winkler E, Haik J. A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J. Cosmet. Laser Ther.9(1), 23–25 (2007).
   PubMedGoogle Scholar
• Bodendorf MO, Grunewald S, Wetzig T, Simon JC, Paasch U. Fractional laser skin therapy. J. Dtsch Dermatol. Ges. (2008).
   Google Scholar
• Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J. Am. Acad. Dermatol.58(5), 719–737 (2008).
   PubMed Web of Science ®Google Scholar
• Christiansen K, Bjerring P. Low density, non-ablative fractional CO2 laser rejuvenation. Lasers Surg. Med.40(7), 454–460 (2008).
   PubMed Web of Science ®Google Scholar
• Lapidoth M, Yagima Odo ME, Odo LM. Novel use of erbium:YAG (2,940-nm) Laser for fractional ablative photothermolysis in the treatment of photodamaged facial skin: a pilot study. Dermatol. Surg.34(8), 1048–1053 (2008).
   PubMed Web of Science ®Google Scholar
• Trelles MA, Velez M, Mordon S. Correlation of histological findings of single session Er:YAG skin fractional resurfacing with various passes and energies and the possible clinical implications. Lasers Surg. Med.40(3), 171–177 (2008).
   PubMedGoogle Scholar
• Cohen SR, Henssler C, Horton K, Broder KW, Moise-Broder PA. Clinical experience with the Fraxel SR laser: 202 treatments in 59 consecutive patients. Plast. Reconstr. Surg.121(5), 297E–304E (2008).
   PubMed Web of Science ®Google Scholar
• Foster KW, Kouba DJ, Fincher EE et al. Early improvement in rhytides and skin laxity following treatment with a combination fractional laser emitting two wavelengths sequentially. J. Drugs Dermatol.7(2), 108–111 (2008).
   PubMed Web of Science ®Google Scholar
• Dierickx CC, Khatri KA, Tannous ZS et al. Micro-fractional ablative skin resurfacing with two novel erbium laser systems. Lasers Surg. Med.40(2), 113–123 (2008).
   PubMed Web of Science ®Google Scholar
• Trelles MA, Mordon S, Velez M, Urdiales F, Levy JL. Results of fractional ablative facial skin resurfacing with the erbium:yttrium-aluminium-garnet laser 1 week and 2 months after one single treatment in 30 patients. Lasers Med. Sci. DOI: 10.1007/s10103-008-0545-3 (2008) (Epub ahead of print).
   Google Scholar
• Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. Dermatol. Surg.34(3), 301–305 (2008).
   PubMed Web of Science ®Google Scholar
• Jih MH, Goldberg LH, Kimyai-Asadi A. Fractional photothermolysis for photoaging of hands. Dermatol. Surg.34(1), 73–78 (2008).
   PubMed Web of Science ®Google Scholar
• Clementoni MT, Gilardino P, Muti GF, Beretta D, Schianchi R. Non-sequential fractional ultrapulsed CO2 resurfacing of photoaged facial skin: preliminary clinical report. J. Cosmet. Laser Ther.9(4), 218–225 (2007).
   PubMedGoogle Scholar
• Alexiades-Armenakas M. Fractional laser resurfacing. J. Drugs Dermatol.6(7), 750–751 (2007).
   PubMedGoogle Scholar
• Collawn SS. Fraxel skin resurfacing. Ann. Plast. Surg.58(3), 237–240 (2007).
   PubMed Web of Science ®Google Scholar
• Hantash BM, Bedi VP, Kapadia B et al.In vivo histological evaluation of a novel ablative fractional resurfacing device. Lasers Surg. Med.39(2), 96–107 (2007).
   PubMed Web of Science ®Google Scholar
• Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg. Med.39(2), 87–95 (2007).
   PubMed Web of Science ®Google Scholar
• Geronemus RG. Fractional photothermolysis: current and future applications. Lasers Surg. Med.38(3), 169–176 (2006).
   PubMed Web of Science ®Google Scholar
• Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg. Med.38(2), 142–149 (2006).
   PubMed Web of Science ®Google Scholar
• Rostan EF. Laser treatment of photodamaged skin. Facial Plast. Surg.21(2), 99–109 (2005).
   PubMedGoogle Scholar
• Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg. Med.34(5), 426–438 (2004).
   PubMed Web of Science ®Google Scholar
• Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch. Dermatol.143(11), 1450–1452 (2007).
   PubMedGoogle Scholar
• Piaserico S, Belloni Fortina A, Rigotti P et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant. Proc.39(6), 1847–1850 (2007).
   PubMed Web of Science ®Google Scholar
• Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of non-melanoma skin cancer. Dermatol. Surg30(2 Pt 2), 264–271 (2004).
   PubMed Web of Science ®Google Scholar
• Britton JE, Goulden V, Stables G, Stringer M, Sheehan-Dare R. Investigation of the use of the pulsed dye laser in the treatment of Bowen’s disease using 5-aminolaevulinic acid phototherapy. Br. J. Dermatol.153(4), 780–784 (2005).
   PubMed Web of Science ®Google Scholar
• Strasswimmer J, Grande DJ. Do pulsed lasers produce an effective photodynamic therapy response? Lasers Surg. Med.38(1), 22–25 (2006).
   PubMed Web of Science ®Google Scholar
• Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin. Dermatol.24(1), 16–25 (2006).
   PubMed Web of Science ®Google Scholar
• Karrer S, Baumler W, Abels C, Hohenleutner U, Landthaler M, Szeimies RM. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo.Lasers Surg. Med.25(1), 51–59 (1999).
   PubMed Web of Science ®Google Scholar
• Kelly KM, Kimel S, Smith T et al. Combined photodynamic and photothermal induced injury enhances damage to in vivo model blood vessels. Lasers Surg. Med.34(5), 407–413 (2004).
   PubMed Web of Science ®Google Scholar
• Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic cheilitis. J. Drugs Dermatol.3(5), 548–551 (2004).
   PubMedGoogle Scholar
• Ruiz-Rodriguez R, Lopez L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J. Drugs Dermatol.6(8), 818–820 (2007).
   PubMedGoogle Scholar